This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Company News for May 26, 2020
by Zacks Equity Research
Companies In The News Are: TTWO, XERS, SPLK, NAVB
Is the Options Market Predicting a Spike in T2 Biosystems (TTOO) Stock?
by Zacks Equity Research
Investors need to pay close attention to T2 Biosystems (TTOO) stock based on the movements in the options market lately.
T2 Biosystems (TTOO) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
T2 Biosystems' (TTOO) first-quarter performance is likely to reflect growth in product revenues.
Is the Options Market Predicting a Spike in T2 Biosystems (TTOO) Stock?
by Zacks Equity Research
Investors need to pay close attention to T2 Biosystems (TTOO) stock based on the movements in the options market lately.
Analysts Estimate T2 Biosystems (TTOO) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
T2 Biosystems (TTOO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: T2 Biosystems (TTOO) Q3 Earnings Expected to Decline
by Zacks Equity Research
T2 Biosystems (TTOO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Are Options Traders Betting on a Big Move in T2 Biosystems (TTOO) Stock?
by Zacks Equity Research
Investors need to pay close attention to T2 Biosystems (TTOO) stock based on the movements in the options market lately.
T2 Biosystems (TTOO) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
T2 Biosystems (TTOO) delivered earnings and revenue surprises of -9.38% and -10.07%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
T2 Biosystems (TTOO) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
T2 Biosystems (TTOO) delivered earnings and revenue surprises of -13.33% and 31.83%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Can Mass Cytometry Drive Fluidigm's (FLDM) Q1 Earnings?
by Zacks Equity Research
Better-than-expected performance at mass cytometry market and higher revenues is likely to aid Fluidigm's (FLDM) in Q1 earnings. However, sluggishness in microfluidics market remains a dampener.
Integer Holdings (ITGR) Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Better-than-expected performance at C&V and Cardiac & Neuromodulation product lines and higher revenues might aid Integer Holdings (ITGR) in Q1. But decline in non-medical sales might be a dampener.
T2 Biosystems (TTOO) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
T2 Biosystems (TTOO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is the Options Market Predicting a Spike in T2 Biosystems (TTOO) Stock?
by Zacks Equity Research
Investors need to pay close attention to T2 Biosystems (TTOO) stock based on the movements in the options market lately.
Zacks.com featured highlights include: Ralph Lauren, Estee Lauder, GMS, CytRx and T2 Biosystems
by Zacks Equity Research
Zacks.com featured highlights include: Ralph Lauren, Estee Lauder, GMS, CytRx and T2 Biosystems
Bet on Rising P/E Investing With These 5 Top-Ranked Stocks
by Sanghamitra Saha
Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.
4 Medical Device Stocks to Top Q3 Earnings
by Zacks Equity Research
A look at how medical device players are poised for this earnings season.
5 Medtech Stocks to Steer Clear of Amid Political Chaos
by Zacks Equity Research
In view of the current political scenario and unfavorable metrics, these five MedTech stocks are best avoided for now.
Zacks Industry Outlook Highlights: Varian Medical Systems, T2 Biosystems, Edwards Lifesciences, INSYS Therapeutics and Cerner
by Zacks Equity Research
Zacks Industry Outlook Highlights: Varian Medical Systems, T2 Biosystems, Edwards Lifesciences, INSYS Therapeutics and Cerner
MedTech Industry Outlook - March 2017
by Zacks Equity Research
A shrinking customer base indicates an impending slash in the demand for expensive medical procedures and devices.
5 MedTech Stocks Poised to Trump Earnings in Q4
by Zacks Equity Research
MedTech's steady earnings trend reflects a strong product cycle and continuing innovation.